Zusammenfassung
Kutane Lymphome sind überwiegend Erkrankungen des älteren und alten Menschen. Ihr Management erfordert eine stadiengerechte Therapie, d. h. frühe Stadien und indolente Formen können im allgemeinen mit lokalen Therapien behandelt werden, während spätere Stadien und aggressivere Varianten eine systemische Therapie erfordern. Explizite Therapieempfehlungen speziell für geriatrische Patienten existieren auf Grund der Seltenheit der Erkrankung und mangelnde durch vergleichende Studien belegte Evidenz nicht. Dabei besteht gerade für diese Patientengruppe ein erhöhtes Risiko, da ein hohes Alter einen negativen prognostischen Marker für kutane T-Zell-Lymphome darstellt und sich aggressivere B-Zell-Lymphome auch fast ausschließlich bei hochbetagten Patienten entwickeln. Trotz mangelnder altersspezifischer Therapieempfehlung muss die Therapieentscheidung bei geriatrischen Patienten häufig sehr individuell getroffen werden, da viele Kontraindikationen und Komorbiditäten speziell im höheren Patientenalter das Erstlinientherapiespektrum einschränken und ein Ausweichen auf alternative Optionen notwendig machen.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Literatur
Amber KT, Bloom R, Nouri K (2016) Second primary malignancies in CTCL patients from 1992 to 2011: a SEER-based, population-based study evaluating time from CTCL diagnosis, age, sex, stage, and CD30+ subtype. Am J Clin Dermatol 17:71–77
Arcari A, Chiappella A, Spina M, Zanlari L, Bernuzzi P, Valenti V, Tani M, Marasca R, Cabras MG, Zambello R et al (2015) Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study. Leuk Lymphoma 2016 Aug 57(8):1823–1830
Assaf C, Bagot M, Dummer R, Duvic M, Gniadecki R, Knobler R, Ranki A, Schwandt P, Whittaker S (2006) Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion. Br J Dermatol 155:261–266
Bessell EM, Humber CE, O’Connor S, English JS, Perkins W, Dickinson PD, Patel AN (2012) Primary cutaneous B-cell lymphoma in Nottinghamshire U.K.: prognosis of subtypes defined in the WHO-EORTC classification. Br J Dermatol 167:1118–1123
Chatterjee K, Zhang J, Honbo N, Karliner JS (2010) Doxorubicin cardiomyopathy. Cardiology 115:155–162
DeSimone JA, Sodha P, Ignatova D, Dummer R, Cozzio A, Guenova E (2015) Recent advances in primary cutaneous T-cell lymphoma. Curr Opin Oncol 27:128–133
Duvic M, Donato M, Dabaja B, Richmond H, Singh L, Wei W, Acholonu S, Khouri I, Champlin R, Hosing C (2010) Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome. J Clin Oncol 28:2365–2372
Eder J, Kern A, Moser J, Kitzwogerer M, Sedivy R, Trautinger F (2015) Frequency of primary cutaneous lymphoma variants in Austria: retrospective data from a dermatology referral centre between 2006 and 2013. J Eur Acad Dermatol Venereol 29:1517–1523
Elsayad K, Kriz J, Moustakis C, Scobioala S, Reinartz G, Haverkamp U, Willich N, Weishaupt C, Stadler R, Sunderkotter C et al (2015) Total skin electron beam for primary cutaneous T-cell lymphoma. Int J Radiat Oncol Biol Phys 93:1077–1086
Fabbri A, Cencini E, Alterini R, Rubegni P, Rigacci L, Delfino C, Puccini B, Fimiani M, Bosi A, Bocchia M et al (2014) Rituximab plus liposomal pegylated doxorubicin in the treatment of primary cutaneous B-cell lymphomas. Eur J Haematol 93:129–136
Feenstra J, Grobbee DE, Remme WJ, Stricker BH (1999) Drug-induced heart failure. J Am Coll Cardiol 33:1152–1162
Grange F, Maubec E, Bagot M, Beylot-Barry M, Joly P, Dalle S, Delaporte E, Dereure O, Bachelez H, Vergier B et al (2009) Treatment of cutaneous B-cell lymphoma, leg type, with age-adapted combinations of chemotherapies and rituximab. Arch Dermatol 145:329–330
Grange F, Joly P, Barbe C, Bagot M, Dalle S, Ingen-Housz-Oro S, Maubec E, D’Incan M, Ram-Wolff C, Dalac S et al (2014) Improvement of survival in patients with primary cutaneous diffuse large B-cell lymphoma, leg type, in France. JAMA Dermatol 150:535–541
Heumann TR, Esiashvili N, Parker S, Switchenko JM, Dhabbaan A, Goodman M, Lechowicz MJ, Flowers CR, Khan MK (2015) Total skin electron therapy for cutaneous T-cell lymphoma using a modern dual-field rotational technique. Int J Radiat Oncol Biol Phys 92:183–191
Hoppe RT, Harrison C, Tavallaee M, Bashey S, Sundram U, Li S, Million L, Dabaja B, Gangar P, Duvic M et al (2015) Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: results of a pooled analysis from 3 phase-II clinical trials. J Am Acad Dermatol 72:286–292
Hosing C, Bassett R, Dabaja B, Talpur R, Alousi A, Ciurea S, Popat U, Qazilbash M, Shpall EJ, Oki Y et al (2015) Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution. Ann Oncol 26:2490–2495
Hughes CF, Khot A, McCormack C, Lade S, Westerman DA, Twigger R, Buelens O, Newland K, Tam C, Dickinson M et al (2015) Lack of durable disease control with chemotherapy for mycosis fungoides and Sezary syndrome: a comparative study of systemic therapy. Blood 125:71–81
Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C (2014) Primary cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome): part II. Prognosis, management, and future directions. J Am Acad Dermatol 70:223 e1–223 e17; quiz 240–222
Kamstrup MR, Lindahl LM, Gniadecki R, Iversen L, Skov L, Petersen PM, Loft A, Specht L (2012) Low-dose total skin electron beam therapy as a debulking agent for cutaneous T-cell lymphoma: an open-label prospective phase II study. Br J Dermatol 166:399–404
Khakoo AY, Halushka MK, Rame JE, Rodriguez ER, Kasper EK, Judge DP (2005) Reversible cardiomyopathy caused by administration of interferon alpha. Nat Clin Pract Cardiovasc Med 2:53–57
Kim YH, Willemze R, Pimpinelli N, Whittaker S, Olsen EA, Ranki A, Dummer R, Hoppe RT (2007) TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 110:479–484
Korgavkar K, Weinstock MA (2014) Changing incidence trends of cutaneous B-cell lymphoma. J Invest Dermatol 134:840–842
Litvinov IV, Tetzlaff MT, Rahme E, Jennings MA, Risser DR, Gangar P, Netchiporouk E, Moreau L, Prieto VG, Sasseville D et al (2015) Demographic patterns of cutaneous T-cell lymphoma incidence in Texas based on two different cancer registries. Cancer Med 4:1440–1447
Massone C, Fink-Puches R, Wolf I, Zalaudek I, Cerroni L (2015) Atypical clinicopathologic presentation of primary cutaneous diffuse large B-cell lymphoma, leg type. J Am Acad Dermatol 72:1016–1020
Nicolay JP, Klemke CD (2014) Management of cutaneous lymphomas. Hautarzt 65:607–613
Nicolay JP, Muller-Decker K, Schroeder A, Brechmann M, Mobs M, Geraud C, Assaf C, Goerdt S, Krammer PH, Gulow K (2016) Dimethyl fumarate restores apoptosis sensitivity and inhibits tumor growth and metastasis in CTCL by targeting NFkappaB. Blood 128:805
Ohmachi K, Niitsu N, Uchida T, Kim SJ, Ando K, Takahashi N, Uike N, Eom HS, Chae YS, Terauchi T et al (2013) Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 31:2103–2109
Oka T, Sugaya M, Cury-Martins J, Vasconcelos-Berg R, Suga H, Miyagaki T, Scheinberg P, Fujita H, Izutsu K, Sato S et al (2016) Hematopoietic stem cell transplantation for cutaneous T-cell lymphoma: summary of 11 cases from two facilities in Japan and Brazil. J Dermatol 43:638–642
Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, Zackheim H, Duvic M, Estrach T, Lamberg S et al (2007) Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 110:1713–1722
Polansky M, Talpur R, Daulat S, Hosing C, Dabaja B, Duvic M (2015) Long-term complete responses to combination therapies and allogeneic stem cell transplants in patients With Sezary syndrome. Clin Lymphoma Myeloma Leuk 15:e83–e93
Prince HM, Whittaker S, Hoppe RT (2009) How I treat mycosis fungoides and Sezary syndrome. Blood 114:4337–4353
Savini P, Lanzi A, Foschi FG, Marano G, Stefanini GF (2014) Lenalidomide monotherapy in relapsed primary cutaneous diffuse large B cell lymphoma-leg type. Ann Hematol 93:333–334
Scarisbrick JJ, Prince HM, Vermeer MH, Quaglino P, Horwitz S, Porcu P, Stadler R, Wood GS, Beylot-Barry M, Pham-Ledard A et al (2015) Cutaneous Lymphoma International Consortium Study of outcome in advanced stages of mycosis fungoides and Sezary syndrome: effect of specific prognostic markers on survival and development of a prognostic model. J Clin Oncol 33:3766–3773
Senff NJ, Noordijk EM, Kim YH, Bagot M, Berti E, Cerroni L, Dummer R, Duvic M, Hoppe RT, Pimpinelli N et al (2008) European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood 112:1600–1609
Sidbury R, Davis DM, Cohen DE, Cordoro KM, Berger TG, Bergman JN, Chamlin SL, Cooper KD, Feldman SR, Hanifin JM et al (2014) Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol 71:327–349
Sonnenblick M, Rosin A (1991) Cardiotoxicity of interferon. A review of 44 cases. Chest 99:557–561
Stadler R, Assaf C, Klemke CD, Nashan D, Weichenthal M, Dummer R, Sterry W (2013) Brief S2k guidelines – cutaneous lymphomas. J Dtsch Dermatol Ges: J Ger Soc Dermatol: JDDG 11(Suppl 3):19–28, 20–30
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127:2375–2390
Thieblemont C, Coiffier B (2007) Lymphoma in older patients. J Clin Oncol 25:1916–1923
Vacirca JL, Acs PI, Tabbara IA, Rosen PJ, Lee P, Lynam E (2014) Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma. Ann Hematol 93:403–409
Wilson LD, Hinds GA, Yu JB (2012) Age, race, sex, stage, and incidence of cutaneous lymphoma. Clin Lymphoma Myeloma Leuk 12:291–296
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2018 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature
About this chapter
Cite this chapter
Nicolay, J.P., Goerdt, S. (2018). Kutane Lymphome beim alten und geriatrischen Patienten. In: Ebert, M., Härtel, N., Wedding, U. (eds) Geriatrische Onkologie. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-48727-3_43
Download citation
DOI: https://doi.org/10.1007/978-3-662-48727-3_43
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-48726-6
Online ISBN: 978-3-662-48727-3
eBook Packages: Medicine (German Language)